Drug intelligence / Profile preview

AFC-5128

Development stage: Preclinical
Lead developer: Lead Discovery Center
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

AFC-5128 is a CNS-penetrant, orally active small molecule antagonist of the purinergic P2X7 receptor, developed primarily for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and neuropathic pain. Its mechanism of action involves inhibiting the P2X7 receptor on CNS-resident immune cells (such as microglia), reducing ATP-stimulated calcium influx, T-cell proliferation, and neuroinflammation, which suggests potential benefit in both progressive and relapsing forms of multiple sclerosis[1][3][4][5][7][9].

Other names: AFC-5128AFC5128AFC 5128AFC-5261AFC5261AFC 5261AffectisP2X7 purinoreceptor antagonistP-2X7 purinoreceptor antagonistP 2X7 purinoreceptor antagonist

Targets

P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on AFC-5128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFC-5128.

Explore the full profile